Definium Therapeutics, Inc.
DFTX$488M
Small CapNASDAQMedicinal Chemicals & Botanical ProductsBiotechnology🇺🇸North AmericaNEW YORK57 employees
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
5wMarket Overview
Stock performance and key metrics
DFTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
DT120
Major Depressive Disorder
MM-120 (LSD D-Tartrate)
Anxiety Generalized
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
DT120 | Phase 3 | Major Depressive Disorder | - | - |
MM-120 (LSD D-Tartrate) | Phase 2 | Anxiety Generalized | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply